Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist.
The separation and biological evaluation of rotamers as well as interconversion studies on rotamers of our clinical candidate SCH 351125 are described.
Palani
Anandan
A
Chemical Research, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. anandan.palani@spcorp.com
Shapiro
Sherry
S
Clader
John W
JW
Greenlee
William J
WJ
Blythin
David
D
Cox
Kathleen
K
Wagner
Nicole E
NE
Strizki
Julie
J
Baroudy
Bahige M
BM
Dan
Niya
N
D019380:Anti-HIV Agents / Q000737:chemistry* / Q000494:pharmacology; D001682:Biological Availability; D065100:CCR5 Receptor Antagonists; D018946:Chemokine CCL5 / Q000037:antagonists & inhibitors; D002851:Chromatography, High Pressure Liquid; D003497:Cyclic N-Oxides / Q000737:chemistry* / Q000494:pharmacology*; D006678:HIV / Q000187:drug effects; D006801:Humans; D020128:Inhibitory Concentration 50; D007536:Isomerism; D010091:Oximes; D010880:Piperidines; D011725:Pyridines / Q000737:chemistry* / Q000494:pharmacology*; D013237:Stereoisomerism
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D018946:Chemokine CCL5; D003497:Cyclic N-Oxides; D010091:Oximes; D010880:Piperidines; D011725:Pyridines; C438583:Ancriviroc